The COX-2 inhibitor market has gotten heated up with launched of generics and new drugs

Pfizer has made movements to prevent the ‘Sales Cliff’ phenomenon in which sales decline after the patent expiration of the selective COX-2 inhibitor ‘Celebrex (generic name: celecoxib)’ that will be expired in June this year.

Followed by the expiration, several top domestic pharmaceutical companies have already made forthcoming announcements to launch its generics or even COX-2 inhibitor type...